Zymo Research partnered with Stori to commercialize a cfDNA-based early pregnancy test built around Zymo’s sample preservation and cfDNA extraction technologies. The companies said the test can detect placental DNA as early as five weeks, using maternal capillary blood collected at home and shipped to a CLIA lab for PCR testing. Zymo said Stori will serve as the exclusive commercialization partner, with both firms running clinical studies to characterize assay performance. The pipeline initially includes applications such as prenatal biological sex determination. Financial terms were not disclosed. The deal highlights the increasing push toward home-sampling workflows and sensitive nucleic-acid analysis for high-frequency reproductive health decisions.